newsfilter
← Latest News
GlobeNewswire·

Chemed Reports First-Quarter 2026 Results

CHE
  • Chemed Corporation reported first-quarter 2026 consolidated revenue of $657.5 million, an increase of 1.6% from the prior year.
  • GAAP diluted EPS was $4.84, a decrease of 0.4%, while adjusted diluted EPS was $5.65, an increase of 0.4%.
  • VITAS segment net patient revenue rose 3.1% to $420.0 million, driven by a 2.2% increase in average daily census & a 6.9% rise in admissions.
  • Roto-Rooter segment revenue declined 0.9% to $237.5 million, with commercial revenue down 1.9% & residential revenue down 1.5%.
  • The company repurchased 500,000 shares of its stock for $197.7 million, equivalent to $395.36 per share.
  • Chemed acquired two Roto-Rooter franchises in San Francisco & Fort Worth for a combined $20.6 million to boost market share.
  • Full-year 2026 adjusted diluted EPS guidance was increased to a range of $24.00 to $24.75, up from the previous range of $23.25 to $24.25.
  • VITAS 2026 average daily census growth guidance was revised upward to 4.5% to 5.5%, compared to the original 3.5% to 4.0%.
  • VITAS 2026 revenue growth guidance (excluding Medicare Cap) was raised to 6.5% to 7.5%, up from the original 5.5% to 6.5%.
  • Roto-Rooter 2026 revenue growth guidance remains unchanged at 3.0% to 3.5%, though adjusted EBITDA margin guidance was lowered slightly to 21.5% to 22.5%.
  • Roto-Rooter faced headwinds including ice & snowstorms causing an estimated $3 million to $4 million revenue loss & elevated marketing expenses exceeding expectations by $2.0 million.
  • Chemed secured a new five-year $450 million credit agreement in April 2026 with a floating rate of SOFR plus 100 basis points.
  • As of March 31, 2026, the company held $16.9 million in cash & cash equivalents against $91.2 million in long-term debt.
  • A conference call to discuss results is scheduled for April 24, 2026, at 10 a.m. ET.